<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02825979</url>
  </required_header>
  <id_info>
    <org_study_id>H16-00617</org_study_id>
    <nct_id>NCT02825979</nct_id>
  </id_info>
  <brief_title>Early Aggressive Invasive Intervention for Atrial Fibrillation</brief_title>
  <acronym>EARLY-AF</acronym>
  <official_title>Early Aggressive Invasive Intervention for Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jason Andrade</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The EARLY-AF study is centered on an evaluation of the impact of the early invasive
      management of Atrial Fibrillation. The primary goal of the study is to evaluate the clinical
      effectiveness of an early invasive approach. Specifically, the investigators are aiming to
      evaluate if PVI performed with the Arctic Front cryoballoon is superior to AAD as first-line
      therapy in preventing atrial arrhythmia recurrences (arrhythmia related symptoms,
      hospitalisations, and health care utilization).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The EARLY-AF study is centered on an evaluation of the impact of the early invasive
      management of Atrial Fibrillation.

      All patients will undergo a loop recorder implantation (REVEAL LINQ, Medtronic), also called
      an insertable cardiac monitor (ICM), at the time of study enrolment using standard clinical
      implant procedures.

      The primary goal of the study is to evaluate the clinical effectiveness of an early invasive
      approach. Specifically, the investigators are aiming to evaluate if PVI performed with the
      Arctic Front cryoballoon is superior to AAD as first-line therapy in preventing atrial
      arrhythmia recurrences (arrhythmia related symptoms, hospitalisations, and health care
      utilization).

      The secondary goal of the program is to evaluate the health related quality of life (HRQOL)
      impact associated with early invasive intervention, in comparison to primary AAD therapy.
      This analysis will be centered on an evaluation of generic and disease-specific HRQOL
      instruments in order to determine the impact of an early invasive approach. A secondary
      benefit is the derivation of a Quality Adjusted Life Years (QALYs) score, which can be used
      as a summary measure of health outcome and to inform subsequent healthcare resource
      allocation decisions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to recurrence of symptomatic or asymptomatic Atrial Fibrillation, Atrial Flutter or Atrial Tachycardia</measure>
    <time_frame>Time to first recurrence between days 91 and 365 post randomization.</time_frame>
    <description>The single procedure success (in the absence of AAD) is defined as the time to first recurrence of symptomatic** or asymptomatic AF, atrial flutter, or atrial tachycardia (AF/AFL/AT) documented by 12-lead ECG, surface ECG rhythm strips, ambulatory ECG monitor, or on implantable loop recorder and lasting 120 seconds or longer as adjudicated by a blinded group of investigators between days 91 and 365 post randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence of symptomatic AF/AFL/AT</measure>
    <time_frame>Time to first recurrence between day 0 and 365 post Ablation</time_frame>
    <description>Time to first recurrence of symptomatic documented AF/AFL/AT between days 91 and 365 after ablation or a repeat ablation procedure between days 0 and 365 post ablation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total arrhythmia burden</measure>
    <time_frame>60 months</time_frame>
    <description>Total arrhythmia burden (daily AF burden - hours/day; overall AF burden - % time in AF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major complications of ablation, or significant adverse drug events (death, ventricular pro-arrhythmia, syncope, hypotension requiring hospitalisation, pacemaker insertion).</measure>
    <time_frame>Acute peri-procedural complications will be defined as occurring within 30 days of ablation, with delayed complications occurring 31-365 days after ablation.</time_frame>
    <description>Events include events death, ventricular pro-arrhythmia, syncope, hypotension requiring hospitalisation, pacemaker insertion).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">298</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Cryoballoon-based PVI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sinus rhythm control via a pulmonary vein isolation (PVI) (&quot;first-line&quot;) procedure utilizing the the Arctic Front Cryoballoon Procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-Arrhythmic Drug Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sinus rhythm control via the use of anti-arrhythmic drug (AAD) therapy (&quot;first-line&quot;) based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryoballoon-based PVI</intervention_name>
    <description>Patients randomized to first-line cryoballoon (CB) ablation will have the pulmonary vein isolation procedure performed according to standard clinical practice using the Arctic Front Cryoballoon ablation catheter. No anti-arrhythmic drugs will be prescribed in this arm.</description>
    <arm_group_label>Cryoballoon-based PVI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-Arrhythmic Drug Therapy</intervention_name>
    <description>Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.</description>
    <arm_group_label>Anti-Arrhythmic Drug Therapy</arm_group_label>
    <other_name>sotalol, flecainide, propafenone, dronedarone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-permanent AF documented on a 12 lead ECG, Trans Telephonic Monitoring (TTM) or
             Holter monitor within the last 24 months

          -  Age of 18 years or older on the date of consent

          -  Candidate for ablation based on AF that is symptomatic

          -  Informed Consent

        Exclusion Criteria:

          -  Regular (daily) use of a class 1 or 3 antiarrhythmic drug (pill-in-the-pocket AAD use
             is permitted) at sufficient therapeutic doses according to guidelines (flecainide &gt;50
             mg BID, sotalol &gt;80 mg BID, propafenone &gt;150 mg BID

          -  Previous left atrial (LA) ablation or LA surgery

          -  AF due to reversible cause (e.g. hyperthyroidism, cardiothoracic surgery)

          -  Active Intracardiac Thrombus

          -  Pre-existing pulmonary vein stenosis or PV stent

          -  Pre-existing hemidiaphragmatic paralysis

          -  Contraindication to anticoagulation or radiocontrast materials

          -  Left atrial anteroposterior diameter greater than 5.5 cm by transthoracic
             echocardiography

          -  Cardiac valve prosthesis

          -  Clinically significant (moderately-severe, or severe) mitral valve regurgitation or
             stenosis

          -  Myocardial infarction, PCI / PTCA, or coronary artery stenting during the 3-month
             period preceding the consent date

          -  Cardiac surgery during the three-month interval preceding the consent date

          -  Significant congenital heart defect (including atrial septal defects or PV
             abnormalities but not including PFO)

          -  NYHA class III or IV congestive heart failure

          -  Left ventricular ejection fraction (LVEF) less than 35%

          -  Hypertrophic cardiomyopathy (septal or posterior wall thickness &gt;1.5 cm)

          -  Significant Chronic Kidney Disease (CKD - eGFR &lt;30 µMol/L)

          -  Uncontrolled hyperthyroidism

          -  Cerebral ischemic event (strokes or TIAs) during the six-month interval preceding the
             consent date

          -  Pregnancy

          -  Life expectancy less than one (1) year

          -  Currently participating or anticipated to participate in any other clinical trial of a
             drug, device or biologic that has the potential to interfere with the results of this
             study

          -  Unwilling or unable to comply fully with study procedures and follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Andrade, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason Andrade, M.D.</last_name>
    <phone>604 875-5069</phone>
    <email>jasonandrade@me.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Libin CV Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Rizkallah, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Alexandra</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evan Lockwood, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Zachary Laksman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Andrade, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jason Andrade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Victoria Cardiac Arrhythmia Trials</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Novak, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. John Sapp, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guy Amit, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Mary's Kitchener</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2M 1B2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Umjeet Jolly, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Leong-Sit, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Atul Verma, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rouge Valley Health System</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Yung, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Angaran, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vidal Essebag, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital du Sacré-Cœur de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Quebec</name>
      <address>
        <city>Quebec city</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Champagne, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Le Centre hospitalier universitaire de Sherbrooke CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Francois Roux, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Stephan Wardell, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2016</study_first_submitted>
  <study_first_submitted_qc>July 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Jason Andrade</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flecainide</mesh_term>
    <mesh_term>Sotalol</mesh_term>
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
    <mesh_term>Propafenone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

